BRAF and neoplasm: According to the mathematical term (ψ) identified for every individual tumor for each model (see Supplemental Data Sheet 1), an additive to synergistic response to combination therapy was seen in the double-mutant HCT116 xenograft (average ψ = 1.44 ± 0.42), while a generally additive response was noted in the double-mutant xenograft HCT15 (average ψ = 1.15 ± 0.37), and less than additive effects were observed in the BRAF mutant COLO741 xenograft (average ψ = 0.71 ± 0.54) (Supplemental Data Image 4B).